ATG7 and breast carcinoma: In breast cancer, multiple regulatory axes have been reported, including the T-box transcription factor 15 (TBX15)–microRNA-152 (miR-152)–kinesin family member 2C (KIF2C)–pyruvate kinase M2 (PKM2) pathway contributing to DOX resistance [36], the long noncoding RNA OTUD6B antisense RNA 1 (OTUD6B-AS1)–miR-26a-5p–metadherin (MTDH) pathway conferring DTX resistance [37], and the hsa_circ_0092276–miR-348–ATG7 pathway mediating DOX resistance [38].